Document Detail


Effects of lipoprotein(a) on thrombolysis.
MedLine Citation:
PMID:  8187238     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Lipoprotein(a) (Lp(a)) and plasminogen share a high degree of structural homology. Therefore it has been suggested that elevated levels of Lp(a) may inhibit the profibrinolytic activity at the cell surface and increase the risk of thrombosis by competitive inhibition of plasminogen. In the present study we evaluated whether high levels of Lp(a) affect thrombolytic therapy in patients with acute myocardial infarction. Forty-one patients with acute myocardial infarction were treated with a combination of recombinant tissue-type plasminogen activator and human single-chain urokinase-type plasminogen activator. Coronary patency was assessed angiographically 90 min after initiation of treatment. Thrombolysis was successful in 30 and unsuccessful in 11 patients. Patients with high Lp(a) levels (> 25 mg/dl) (n = 9) responded equally well to thrombolytic therapy (8 of 9, patency 89%) as did patients with normal or low levels of Lp(a) (22 of 32, patency 70%, difference P > 0.1). The results demonstrate that high levels of Lp(a) do not influence thrombolysis in patients with acute myocardial infarction when low-dose pharmacologic concentrations of recombinant tissue-type plasminogen activator and human single chain urokinase-type plasminogen activator are applied in combination.
Authors:
E von Hodenberg; E Pestel; J Kreuzer; M Freitag; C Bode
Related Documents :
9191478 - The acute coronary ischemic syndromes--the central role of thrombosis.
3719448 - Clinical pitfalls in the non-invasive thrombolytic approach to presumed acute myocardia...
2228648 - Clinical controversies surrounding thrombolytic therapy in acute myocardial infarction.
9290398 - Thrombolytic treatment for myocardial infarction: an examination of practice in 39 unit...
542308 - Submucosal cordectomy for laryngeal stenosis.
7933548 - A quantitative estimation of electric current due to myocardial injury.
Publication Detail:
Type:  Clinical Trial; Journal Article    
Journal Detail:
Title:  Chemistry and physics of lipids     Volume:  67-68     ISSN:  0009-3084     ISO Abbreviation:  Chem. Phys. Lipids     Publication Date:  1994 Jan 
Date Detail:
Created Date:  1994-06-23     Completed Date:  1994-06-23     Revised Date:  2009-11-19    
Medline Journal Info:
Nlm Unique ID:  0067206     Medline TA:  Chem Phys Lipids     Country:  IRELAND    
Other Details:
Languages:  eng     Pagination:  381-5     Citation Subset:  IM    
Affiliation:
University of Heidelberg, Department of Cardiology, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Drug Therapy, Combination
Female
Fibrinogen / metabolism
Fibrinolysis / drug effects,  physiology*
Humans
Lipoprotein(a) / blood*
Male
Myocardial Infarction / blood*,  drug therapy*
Plasminogen / metabolism
Recombinant Proteins / administration & dosage,  therapeutic use
Thrombolytic Therapy*
Tissue Plasminogen Activator / administration & dosage,  therapeutic use
Urokinase-Type Plasminogen Activator / administration & dosage,  therapeutic use
alpha-2-Antiplasmin / metabolism
Chemical
Reg. No./Substance:
0/Lipoprotein(a); 0/Recombinant Proteins; 0/alpha-2-Antiplasmin; 9001-32-5/Fibrinogen; 9001-91-6/Plasminogen; EC 3.4.21.68/Tissue Plasminogen Activator; EC 3.4.21.73/Urokinase-Type Plasminogen Activator

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Effects of lipoprotein(a) on the binding of plasminogen to fibrin and its activation by fibrin-bound...
Next Document:  Lipoprotein(a) and coronary heart disease.